Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthr
- PDF / 954,261 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 161 Views
(2020) 22:224
RESEARCH ARTICLE
Open Access
Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study Eric Toussirot1,2,3,4,5* , Hubert Marotte6, Denis Mulleman7, Grégoire Cormier8, Fabienne Coury9, Philippe Gaudin10, Emmanuelle Dernis11, Christine Bonnet12, Richard Damade13, Jean-Luc Grauer14, Tassadit Ait Abdesselam15, Caroline Guillibert-Karras16, Frédéric Lioté17, Pascal Hilliquin18, Antoinette Sacchi19, Daniel Wendling3, Benoît Le Goff20, Marc Puyraveau1,21 and Gilles Dumoulin22
Abstract Background: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with favourable effects on CV disease, especially its high molecular weight (HMW) isoform. Body composition changes are described in RA with various phenotypes including obesity. The effects of tocilizumab on serum adiponectin and body composition, especially fat mass, in patients with RA are not well determined. Methods: Patients with active RA despite previous csDMARDs and/or bDMARDs and who were tocilizumab naïve were enrolled in a multicentre open-label study. They were evaluated at baseline, 1, 3, 6 and 12 months. Clinical assessment included body mass index (BMI) and anthropometric measurements. Lipid and metabolic parameters, serum adiponectin (total and HMW), leptin, resistin and ghrelin were measured at each time point. Body composition (lean mass, fat mass, % fat, fat in the android and gynoid regions) was evaluated at baseline, 6 and 12 months. Results: One hundred seven patients were included. Both total and HMW adiponectin significantly increased from baseline to month 3, peaking respectively at month 3 (p = 0.0105) and month 1 (p < 0.0001), then declining progressively until month 6 to 12 and returning to baseline values. Significant elevation in HMW adiponectin persisted at month 6 (p = 0.001). BMI and waist circumference significantly increased at month 6 and 12, as well as lean mass at month 6 (p = 0.0097). Fat mass, percentage fat and android fat did not change over the study period. (Continued on next page)
* Correspondence: [email protected] 1 INSERM CIC-1431, CHU de Besançon, Centre d’Investigation Clinique Biothérapie, Pôle Recherche, 25000 Besançon, France 2 Fédération Hospitalo-Universitaire INCREASE, CHU de Besançon, 25000 Besançon, France Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a
Data Loading...
